To evaluate the efficacy and safety of short-course therapy with zidovudine plus lamivudine for reduction of perinatal transmission of human immunodeficiency virus type 1 (HIV-1), a single-arm, open-label, prospective, nonrandomized study was conducted. One hundred six treatment-naive pregnant women received zidovudine (300 mg) plus lamivudine (150 mg) twice daily from week 34 of gestation until the onset of labor. During labor, zidovudine and lamivudine were given every 3 h. Neonates received zidovudine syrup for 4 weeks and were bottle fed. The median maternal virus load and CD4 + cell count at weeks 32-34 of gestation were 4.33 log 10 copies/mL and 274 cells/mm 3 , respectively. At delivery, the mothers' mean decrease in virus load was 1.55 log 10 copies/mL and the mean increase in CD4 + cell count was 93 cells/mm 3 , compared with enrollment levels. Three neonates were HIV-1 infected, for a transmission rate of 2.83% (95% confidence interval, 1%-8%). There were no serious adverse events in the mothers. Adverse events noted in neonates were anemia (in 6 neonates), elevated transaminase levels (in 1), and thrombocytopenia (in 3). Short-course therapy with zidovudine plus lamivudine appeared to be safe and effective for prevention of perinatal transmission of HIV-1.
PATIENTS, MATERIALS, AND METHODS
The study was designed as an open-label, nonrandomized, prospective study. From February 1999 through November 2000, women who visited the antenatal clinic at Siriraj Hospital in Bangkok, Thailand, and who were confirmed to be HIV-1 seropositive were counseled regarding their HIV-1 infection status, the antiretroviral regimens available for prevention of mother-to-child transmission of HIV-1, and appropriate infant feeding. Data regarding this study and the option to enroll were given in a nondirective and noncoercive manner. The women who did not enroll in the study received routine short-course zidovudine therapy starting at week 36 of gestation, and the neonate received zidovudine treatment for 4 weeks.
HIV-1-infected pregnant women were eligible to participate in this study if they met the following criteria: age of у18 years; presentation before week 34 of gestation; no history of antiretroviral treatment; healthy status and no previous opportunistic infections; no presence of anemia (hemoglobin concentration, 18 g/dL); normal blood cell count (absolute neutrophil count, у cells/L; platelet count, у platelets/ 9 9 1.0 ϫ 10 100 ϫ 10 L); transaminase enzyme level of !2.5 times the upper limit of normal, normal blood urea nitrogen and serum creatinine levels, and urine protein by dipstick examination of р1ϩ; and willingness to provide voluntary informed consent. Women were excluded from the study if they had a history of intolerance to zidovudine or lamivudine, if they were unable to return for follow-up visits, or if they had prior pregnancies that involved fetal anomalies. Participation in the study was terminated if the patient was not willing to continue use of the medication, was lost to follow-up, had drug intolerance, or had significant adverse drug reactions.
Written consent had to be provided by the enrolled women and, whenever possible, by their husbands. Incentives for study participation included reimbursement of transportation costs for each visit and partial payment of fees for medical care, infant vaccination, and infant formula for at least 12 months.
At study enrollment (weeks 32-34 of gestation), women were interviewed and underwent a physical examination, which included pelvic examination with Papanicolaou smear and chest radiography with an abdominal shield. Chest radiography and pelvic examination with Papanicolaou smear were repeated 6-8 weeks after birth. Venous blood samples were obtained at the time of enrollment, at delivery, and 6-8 weeks after birth for virological and immunological studies, complete blood cell counts, liver function tests, and renal function tests. The women were tested for syphilis and hepatitis B surface antigen during the early and late stages of pregnancy. Urine dipstick examinations were performed at enrollment, at week 38 of gestation, at delivery, and 6-8 weeks after birth.
The treatment regimen used in the study included antepartum oral administration of zidovudine (300 mg) plus lamivudine (150 mg) twice per day, which started at week 34 of gestation and continued until the onset of labor. At the onset of labor, zidovudine and lamivudine were given at the same dose every 3 h until delivery. Study visits were scheduled weekly from week 34 of gestation until delivery and 6-8 weeks, 6 months, 12 months, and 18 months after birth. Cesarean sections were performed only when there was an obstetric indication.
All of the infants born in this study received zidovudine syrup (2 mg/kg every 6 h) for 4 weeks, starting as soon as possible, within a few hours after birth. All of the infants were not breastfed. They were scheduled for study visits at 1, 2, 4, 6, 9, 12, 15, and 18 months of age, consistent with the well baby checkup and routine vaccination schedule. Venous blood samples were obtained at 1-2 days, 1 month, and 4 months of age for detection of HIV-1 RNA and HIV-1 DNA by PCR and for performance of virus coculture, CD4 ϩ cell counts, and complete blood cell counts; samples were obtained at 12 and 18 months of age for detection of anti-HIV-1 antibody. Liver function tests and renal function tests were performed at 1 month of age and were repeated only if an abnormality was found.
The women and their infants were assessed for possible drugrelated toxic effects and adverse events at each visit, in accordance with the AIDS Clinical Trial Group adverse events monitoring guide [9] . Adherence to treatment was assessed by patient interview and pill count. The protocol and consent form were approved by the ethics review committee of the Ministry of Public Health and the Faculty of Medicine at Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Virological study. For determination of the HIV-1 RNA load in the mothers, plasma samples were placed in a citrate tube and quantified by use of the Amplicor HIV-1 Monitor test (Hoffmann LaRoche), which has a cutoff value of 400 copies/mL. Virus loads of !400 copies/mL (i.e., undetectable levels) were recorded as 400 copies/mL for statistical calculation. For the samples from infants, plasma HIV-1 RNA was detected by use of a NucliSens HIV-1 Qualitative/Quantitative kit (Organon Teknika), and the positive RNA results were confirmed by use of the Amplicor HIV-1 Monitor test. HIV-1 DNA was detected with use of an in-house HIV multiplex PCR (gagpol gene). To confirm the positive RNA or DNA PCR results and for further study of the characteristics of the virus, HIV-1 culture was performed with use of peripheral blood mononuclear cells (PBMCs) and a coculture technique.
Diagnosis of HIV-1 infection in infants. For infants, a diagnosis of HIV-1 infection was made if у2 separate blood samples yielded positive results on any virological test (i.e., PCR for detection of HIV-1 DNA or RNA or viral culture) and if samples obtained at the age of у18 months were positive for anti-HIV-1 antibody. The children were considered to be HIV-1 uninfected if у2 separate blood samples (obtained at the ages of у1 month and у4 months) yielded negative results on PCR for detection of HIV-1 DNA or RNA, if the patients tested negative for anti-HIV-1 antibody at the age of у12 months, and if the patients did not have any clinical symptoms or signs associated with HIV-1 infection. Protease and reverse-transcriptase genotyping for drug resistance. The viruses isolated from HIV-1-infected infants and their mothers were genotypically tested for drug resistance. HIV-1 RNA was extracted from plasma samples with a QIAamp Viral RNA extraction kit (QIAGEN). TRUGENE HIV-1 genotyping was used in conjunction with the Open Gene automated DNA sequencing system (Visible Genetics) to sequence the protease and reverse-transcriptase regions of HIV-1 cDNA.
In accordance with the manufacturer's protocol, 1.3 kb of HIV-1 polymerase gene was reverse-transcribed and amplified by RT-PCR in a single tube. The RT-PCR product was sequenced bidirectionally using a CLIP terminator (Visible Genetics) mixed with 3 primer sets specific for the protease and reverse-transcriptase regions of the HIV-1 pol gene. HIV-1 sequence analysis was done with the Open Gene automated DNA sequencing machine. The DNA sequence of the sample was analyzed with TRUGENE software that compared the unknown sequence to a database with known resistance mutations.
Statistical analysis. We used SPSS software, version 9.0 (SPSS), for statistical analysis. Fisher's exact test, the x 2 test, Student's t test, the Mann-Whitney U test, and the Wilcoxon signed rank test were used for comparative measurements, as appropriate. All P values were 2-tailed.
RESULTS
From February 1999 through November 2000, a total of 109 women were enrolled in the study. After delivery, 3 women and their infants were lost to follow-up before the infants' HIV-1 infection status was known. Of the 106 infants who remained in the study, 3 were found to have HIV-1 infection, for a transmission rate of 2.83% (95% CI, 1%-8%).
Of the 97 women who volunteered to disclose their history of risk factors for HIV-1 infection, 5 (5%) used to be commercial sex workers, 87 (90%) reported that their husbands had had multiple sexual partners, and 2 (2%) reported a history of injection drug use by their husbands (table 1) . One woman (0.9%) had late latent syphilis diagnosed, and 8 women (7.5%) were hepatitis B virus carriers. Of the 62 husbands who were also tested for anti-HIV-1 antibody, 18 (29%) were seronegative.
All of the women but 1 attended weekly antenatal visits and had perfect adherence to the drug regimen. The study drugs were well tolerated, and there were no serious adverse events. None of the women discontinued use of the drugs during the antepartum period or missed doses during the intrapartum period.
Sixty-nine (65%) of 106 women had abnormal Papanicolaou smear findings at the time of enrollment (63 women had fungal infection, 4 had human papillomavirus infection, 1 had herpes virus infection, and 1 had dysplasia). At 6-8 weeks after birth, 47 women (44%) still had abnormal Papanicolaou smear findings that indicated infections, although the infections that had been detected earlier were treated appropriately. At the time of enrollment, the median virus load for the mothers was 21,400 copies/mL (4.33 log 10 copies/mL), and the median CD4 ϩ cell count was 274 cells/mm 3 . Eight women had a virus load of !1000 copies/mL. Of these 8 women, 4 had a virus load of !400 copies/mL. At the time of delivery, after the receipt of antepartum treatment for a mean duration of 36 days, the median virus load decreased to 400 copies/mL (2.6 log 10 copies/mL), which was significantly lower than the median virus load noted at the time of enrollment ( ). At the P ! .001 time of delivery, 89 women had a virus load of !1000 copies/ mL, and 76 women had a virus load of !400 copies/mL. The mean decrease in the virus load was 1.55 log 10 copies/mL (95% CI, 1.40-1.69 log 10 copies/mL). After birth, the median virus load for the mothers bounced back to 14,400 copies/mL (4.16 log 10 copies/mL), which was not different from the virus load noted at the time of enrollment ( ). The median CD4 ). The median CD4 ϩ cell count after birth was 538 cells/mm 3 , which is higher than that noted at the time of enrollment, even 6-8 weeks after treatment was discontinued (
; figure 1) . The CD8 ϩ P p .036 cell count was stable from the time of enrollment to the postpartum period (table 2) . There was no correlation between the number of doses of zidovudine and lamivudine administered during the antenatal period and the magnitude of the virus load reduction ( ) or CD4 ϩ cell increase ( ). P p .119 P p .733 There were 16 women (15%) with a hemoglobin level of !10 g/L at the time of enrollment, none of whom transmitted HIV-1 to their children. At the time of delivery, 36 women (34%) who did not transmit HIV-1 to their children and 1 woman who did transmit HIV-1 to her child were anemic, but none had a hemoglobin concentration of !8 g/dL. The number of doses of zidovudine and lamivudine administered was not associated with anemia in the mother at the time of delivery ( ). There were no cases of neutropenia. None of the P p .381 women had elevated transaminase levels (i.e., 12.5 times the normal level; table 1). There were no serious adverse events occurred in the mothers. None of the mothers died. Eightyone women (77%) requested tubal sterilization immediately after delivery.
There were no differences between women who did and women who did not transmit HIV-1 to their children with respect to the number of doses of zidovudine and lamivudine received, CD4
ϩ cell count or virus load at the time of study entry and delivery, increase in CD4 ϩ cell count or decrease in virus load at the time of delivery, mode of delivery, or the occurrence premature rupture of fetal membranes (PROM).
Of the 106 infants, 3 had positive results of HIV-1 PCR on 12 occasions; only 1 of these infants had a positive PCR result at birth. These 3 infants were confirmed to have HIV-1 infection at the age of 18 months by serologic tests positive for anti-HIV-1 antibody. None of these infants had ever been breast-fed. Two infants had congenital abnormalities: one had an atrial septal defect with patent ductus arteriosus and hypoplasia of the aortic arch (number of drug doses received by the mother, 110), and the other had multiple skeletal abnormalities with cleft lip and palate (number of drug doses received by the mother, 38). Both infants were HIV-1 uninfected. Six neonates were anemic at birth (hemoglobin level, !12 g/dL), but none required blood transfusion. All of these neonates were HIV-1 uninfected, and the anemia resolved by 1 month of age without treatment. Three neonates had thrombocytopenia at birth, with platelet counts of 96, 31, and platelets/mm 3 . The first 2 of 3 84 ϫ 10 these neonates were HIV-1 uninfected and had normal platelet counts by 1 month of age. The latter neonate, who was HIV-1 infected, had a normal platelet count by 2 months of age. One neonate had elevated transaminase levels at birth (aspartate aminotransferase level, 184 IU/L; alanine aminotransferase level, 124 IU/L), but the levels returned to normal by 2 months of age. There were no cases of neutropenia. None of the adverse events correlated with the number of doses of zidovudine and lamivudine given to the mother or with any maternal factors (table 3) .
In an attempt to identify the risk factors that caused transmission of HIV-1 to the 3 HIV-1-infected infants, detailed data are shown in table 4. The identifiable risk factors that may have contributed to the transmission were a maternal virus load of 11000 copies/mL (1 case), cervical infection (2 cases), PROM (1 case), low birth weight (1 case), and drug-resistant infection (1 case).
In the ∼6-month period just before this study began, the standard treatment was short-course zidovudine therapy starting at week 36 of gestation plus oral zidovudine administered during the intrapartum period and 4 weeks of zidovudine administered to the neonate. During this period, 7 of 60 infants born to HIV-1-infected mothers were themselves infected, for a transmission rate of 11.67% (95% CI, 5.8%-22.2%). In comparison, the present study noted a significantly lower transmission rate ( ). We also compared the transmission P p .037 rate of this study with that of the first study of short-course zidovudine therapy conducted earlier at our health care center (in 1996-1997); we demonstrated a 50% reduction in the trans- mission rate, to 9.4% [5] . The comparative analysis demonstrated that the regimen of zidovudine and lamivudine used in this study reduced the mothers' virus loads, increased the mothers' CD4 ϩ cell counts, and reduced mother-to-child transmission of HIV-1 more effectively than did short-course zidovudine monotherapy (table 5; ). P p .036
DISCUSSION
Use of the most effective antiretroviral therapy for decreasing the virus load in HIV-1-infected mothers to !1000 copies/mL (the risk of transmission increased at у1000 copies/mL) is recommended for all HIV-1-infected pregnant women to prevent perinatal transmission [12, 13] . However, the majority of women worldwide are not able to receive effective antiretroviral therapy. Studies to look for effective but affordable regimens are needed for developing countries. Because two-thirds of the cases of perinatal transmission occur during the peripartum period, administration of antiretroviral therapy early in the course of pregnancy is less important [14] [15] [16] . Administration of short-course zidovudine therapy to the mother without neonatal treatment has been shown to yield a 50% reduction in the rate of transmission in formula-fed infants [5] . The PETRA study showed that short-course therapy with zidovudine and lamivudine is safe and effective in breast-fed infants, although the percentage reduction in the rate of virus transmission was not much different than that for short-course zidovudine monotherapy in a formula-fed population (50% vs. 51%, respectively) [17] .
Lamivudine has good placental passage with a high amniotic levels, and its pharmacokinetics are not modified by pregnancy [18, 19] . There was no report of teratogenicity or carcinogenicity in an animal study [18] . In addition, the combination of zidovudine and lamivudine has been shown to effectively reduce the virus load [8] . Moreover, zidovudine and lamivudine are locally produced and readily available in Thailand at low cost. For all of these reasons, we chose to study lamivudine in combination with the current standard regimen of short-course zidovudine monotherapy.
Our study of 109 pregnant women has demonstrated that short-course therapy with zidovudine plus lamivudine is apparently safe, and its efficacy is probably better than that of short-course zidovudine monotherapy. The effects on virus load reduction and CD4 ϩ cell increase are also markedly greater for zidovudine plus lamivudine. Because of limited resources, we did not include a control arm in this study. Therefore, for comparison, we used the transmission rate at our institution during the ∼6 months before the initiation of this study. The transmission rate in this study was not different from the rate in a French study (1.6%; 95% CI, 0.7%-3.3%) in which patients received long-course zidovudine therapy plus short-course lamivudine therapy [6] . Moreover, the rate of elective cesarean sections in our study was much lower than that in the French study (4% vs. 22%). We are not able to compare the efficacy in this study with the efficacy in treatment arm A of the PETRA study (treatment with antepartum, intrapartum, and neonatal doses) because of the great difference in the rate of breastfeeding; however, the transmission rate in our study is much lower.
The main mechanism for reduction in the rate of virus transmission associated with zidovudine plus lamivudine therapy is probably the virus load reduction, which was 1.55 log 10 copies/ mL-a greater reduction than that reported for zidovudine monotherapy [5] . This could be because patients in our study were antiretroviral naive. However, neither the number of antenatal nor the total number of doses of zidovudine and lamivudine was found to correlate with the magnitude of the decrease in the virus load or increase in the CD4 ϩ cell count,
and we could not demonstrate the correlation between protection against transmission and the number of drug doses received. We were also not able to demonstrate any factors associated with the transmission risk in this study, probably because of the limited sample size. Three infants were HIV-1 infected, despite a notable reduction in their mothers' virus loads and the recovery of drug-susceptible viral isolates from their mothers. Therefore, drug resistance was not the cause of breakthrough transmission. For each HIV-1-infected infant, there was some other risk factor for infection, such as infection of the mother's genital tract demonstrated on Papanicolaou smear (patients 1 and 2), low birth weight (patient 2), and PROM of 14 h (patient 3). Patient 2 may have been infected in utero before the mother initiated treatment.
Anemia was noted in 5.7% of the neonates exposed to zidovudine and lamivudine, which is very similar to the rate from the French report [6] . However, only 1 case of anemia was severe (hemoglobin concentration, 9.4 g/dL), and none of the patients required blood transfusion. Unlike in the French study, there were no cases of neutropenia in our study, but there were 3 cases of thrombocytopenia. The infants in our study seemed to have fewer adverse events than did those in the French study, in which the mothers started receiving zidovudine and lamivudine therapy earlier in the course of pregnancy (second trimester, for zidovudine, and week 32 of gestation, for lamivudine) and in which the infants also received lamivudine for 6 weeks. The lower rate of adverse events in our study could have resulted from shorter in utero exposure to zidovudine and lamivudine and the absence of lamivudine exposure in the neonates. However, some uncommon adverse events might have occurred had more patients been studied.
The drawback of short-course treatment is the inability to prevent infection in cases of premature birth. Moreover, shortcourse treatment also cannot prevent intrauterine infection if it has occurred before the start of treatment.
In conclusion, we have demonstrated that short-course administration of zidovudine and lamivudine to HIV-1-infected mothers plus administration of zidovudine to neonates is safe and effective for the prevention of mother-to-child transmission of HIV-1. This regimen was probably more effective than short-course zidovudine monotherapy, and it was better tolerated than a longer course of zidovudine and lamivudine that was previously reported in the French study [6] . Short-course administration of zidovudine and lamivudine to mothers plus administration of zidovudine to neonates should be considered an option in settings in which resources are limited.
